Heart Transplantation (ht) from Active and Recently Active Covid19 Donors

HT centers may avoid donors with Covid19 (Cov19) infection due to uncertain risk of virus transmission and possibility of virus mediated myocardial injury. We investigated Cov19 donor utilization, transplant characteristics and early post HT outcomes in the U.S. Between May 2020-June 2022, n=27,862 donors in UNOS had data available on Cov19 NAT tests and organ disposition. Since donors may get Cov19 testing multiple times prior to organ retrieval, additional data on multiple Cov19 NAT was requested and analyzed. Donors were classified Cov19-donors if NAT+ at any time during terminal hospitalization, and subclassified as Active Cov19(A-Cov19) if NAT+ at organ procurement and 'Recently Active Cov19' (rA-Cov19) if NAT+ initially but NAT negative prior to organ retrieval. HT outcomes using Cov19 and nonCov19 donors were compared by Kaplan Meier (KM) and Cox hazards ratio (HR). Prior to organ retrieval, 27,862 donors had 60,699 Cov19 NAT tests done. Of these, n=1445 were Cov19 donors, n=125 indeterminate and n=26,292 nonCov19. Of Cov19 donors, n=1017 were A-Cov19 and n=428 rA-Cov19. 309 HTs used hearts from Cov19 donors and 239 (n=150 A-Cov19, n=89 rA-Cov19) met study criteria. Compared to nonCov19, Cov19 donors used for adult HT were younger [30(23-37) vs 32(25-40)yrs] and mostly male (80.3% vs 72.1%), p<0.05. Otherwise, HTs from Cov19 and nonCov19 donors were similar in recipient age, race, etiology, UNOS status, BMI, LVAD, ECMO use;and donor LVEF, and DCD status. HTs from Cov19 and nonCov19 donors had similar survival up to 3 months [CoxHR=1.23(0.63-2.39), p=0.54, adjusted for baseline characteristics, Fig1A]. Survival was also statistically similar in A-Cov19 and rA-Cov19 donor HT cohorts [CoxHR=1.47(0.40-5.48), p=0.56, Fig1B]. HTs from Cov19 donors increased from n=5 in May-Dec 2020 to n=207 in Jan-June 2022, p<0.05 for trend. Data on Cov19 treatment was not available. In the largest analysis to date, HTs from selective Cov19 donors had acceptable early outcomes. Longer follow up is needed. [ABSTRACT FROM AUTHOR] Copyright of Journal of Heart & Lung Transplantation is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Coronavirus Disease: From Origin to Outbreak

Coronavirus Disease: From Origin to Outbreak provides a comprehensive review of coronaviruses, particularly COVID-19, its transmission, and disease pathology. The book covers the viral structure and genetics of coronaviruses, the pathogenesis and unique characteristics of coronavirus infection, and the evolving nature of our understanding of coronaviruses and disease. It also looks at the history of SARS-CoV and MERS-CoV infections and its global spread. The book examines the effectiveness of various preventive measures and new therapeutic agents that are either currently available or expected to available. Finally, it details the psychological and societal impact the virus and disease has in outbreak regions and what the financial impact an outbreak has on the healthcare system and local economies. © 2022 Elsevier Inc. All rights reserved.

Lactate Dehydrogenase is Associated with Hemorrhagic Stroke During Extracorporeal Membrane Oxygenation for COVID-19

Background: Hemorrhagic stroke (HS) is a devastating complication during extracorporeal membrane oxygenation (ECMO), but markers for risk stratification are unknown. Lactate dehydrogenase (LDH) is a readily available biomarker of global tissue injury and permeability. We sought to determine whether an elevated LDH at baseline is related to eventual HS during ECMO for COVID-19. Method(s): A multicenter, retrospective study was conducted. Adult patients with COVID-19 requiring ECMO between March 2020 and February 2022 were included. LDH values prior to ECMO were captured. Patients were categorized into high (>750 U/L) or low (<=750 U/L) LDH groups. Result(s): There were 520 patients (47+/-11 years old) that underwent ECMO placement in 17 centers and 384 had an available LDH. In this cohort, 122 (32%) had a high LDH. Forty (10%) patients required venoarterial ECMO, while the remaining 344 (90%) received venovenous support only. Twenty-one out of 122 (17%) patients with a high LDH had a HS in comparison to 21 out of 262 (8%) with a low LDH. At 100 days, the probability of a HS was 40% in the high LDH group and 23% in those with a low LDH, p=0.002. After adjustment for age, sex and antecedent cardiopulmonary resuscitation, high LDH was associated with subsequent HS (aHR: 2.73, 95% CI 1.46-5.12). Findings were similar when restricting to patients supported by venovenous ECMO only. Conclusion(s): Elevated LDH prior to ECMO is associated with a HS during device support. LDH can risk stratify cases for impending cerebral bleeding during ECMO.

An Intelligent Electronic Nose for the assistance of Anosmic-Patients

Anosmic people's inability to detect any odors almost always results in unfavorable outcomes. Failure to identify gas leaks or dangerous substances is seen as a threat to their safety. However, as a result of the COVID-19 Pandemic, the number of anosmic patients is steadily increasing. In this paper we propose a system assists anosmic patients in recognizing hazards that they cannot smell. This revolutionary system detects gas leaks, smoke, and early fires, as well as dangerous substances, automatically. With the aid of an array of gas sensors and different machine learning algorithms the, E-nose can identify six distinct smells. At last, if any hazardous gas spread occurs, the system fires alert message specifics the identified gas or event. We succeeded in achieving F1-score of 98 % for Support Vector Machine (SVM), logistic regression, and Decision Tree. While K-nearest Neighbors and Random Forest scored 100%. © 2022 IEEE.

Comparison of cannulation approaches for venovenous extracorporeal membrane oxygenation during covid-19

Purpose: Venovenous extracorporeal membrane oxygenation (VV-ECMO) is performed through various cannulation approaches but an optimal strategy remains uncertain. Methods: A retrospective, multi-center study was conducted. Adult patients (≥18 years old) placed on VV-ECMO for severe respiratory failure due to COVID-19 between March 1, 2020, to April 30, 2021, across the United States were included. Patients were divided into the following 3 groups based on initial cannulation: 1) femoral vein-femoral vein or femoral vein-internal jugular vein (Dual-Site, DS), 2) single, dual-lumen cannula in internal jugular vein with tip positioned in the pulmonary artery (PA) and 3) single, dual-lumen cannula in internal jugular vein with tip positioned in the inferior vena cava (IVC). The primary outcome was in-hospital mortality after VV-ECMO placement assessed by a time-toevent analysis. Results: Overall, 435 patients from 17 centers comprised the study cohort. DS cannulation was performed in 247 (age: 47±11, 30% female) cases, 99 (age 50±12, 26% female) received PA, and 89 patients got IVC (age 45±12, 33% female). At 90 days, in-hospital mortality across cannulation groups was 60% (DS), 41% (PA) and 61% (IVC), p=0.06 (Figure 1). After adjustment for clinical covariates, the likelihood of in-hospital mortality in comparison to DS, was lower with PA (aHR: 0.60, 95%CI 0.40-0.91, p=0.02) and similar with IVC (aHR: 0.99, 95%CI 0.68-1.43, p=0.95). Conclusion: Catheter directed flow into the PA with a single dual-lumen cannula is associated with reduced mortality during VV ECMO for COVID-19.

Direct versus indirect thrombin inhibition during extracorporeal membrane oxygenation support for covid-19

Purpose: Anticoagulation during extracorporeal membrane oxygenation (ECMO) for COVID-19 can be carried out by direct or indirect thrombin inhibition. The former agent obviates monitoring of antithrombin III but differences in outcomes with either approach are uncertain. Methods: A retrospective, multi-center study was conducted. Adult patients (≥18 years old) placed on ECMO for severe respiratory or circulatory failure due to COVID-19 between March 1, 2020, to April 30, 2021, in the United States were included. Patient were divided in 2 groups based on the utilized anticoagulation agent during ECMO support: 1) direct thrombin inhibitor (DTi, e.g. bivalirudin and argatroban) and 2) indirect thrombin inhibitor (IDTi, e.g. unfractionated heparin). The primary outcome was in-hospital mortality after ECMO placement assessed by a time-to-event analysis. Results: Overall, 455 patients from 17 centers were placed on ECMO, of whom 44 were excluded due to no reported anticoagulation agent. DTi was used in 160 (age: 47±11, 28% female) cases and 251 patients received IDTi (age 47±12, 29% female). At 90 days, in-hospital mortality was 50% (DTi) and 61% (IDTi), p=0.08, (Figure). After adjustment for clinical covariates, the likelihood of in-hospital mortality was similar with DTi (aHR: 0.79, 95%CI 0.57-1.10, p=0.16) compared to IDTi. Noted prevalence of deep vein thrombosis (DTi 14%, IDHi 12%), ischemic stroke (DTi 2%, IDHi 3%), intracranial hemorrhage (DTi 11%, IDHi 10%) and bleeding requiring transfusion (DTi 71%, IDHi 83%) was comparable between groups. Conclusion: Anticoagulants that directly or indirectly inhibit thrombin are associated with similar outcomes during ECMO for COVID-19.

Telehealth for Left Ventricular Assist Device Patients: Current Perceptions and Practices in the United States

Purpose Telehealth services increased during the COVID-19 pandemic but barriers to expansion of telemedicine use for LVAD patients are not well described. This study evaluated perceptions of telehealth and patterns of use at LVAD centers across the USA. Methods An online, de-identified, 19 question survey was distributed across the USA to 53 LVAD centers participating in the FLIGHT and IDEAL HF working groups. A maximum of one physician and one VAD coordinator completed the survey at each center. Results The 62 respondents included 34 heart failure cardiologists, 11 cardiothoracic surgeons, 7 LVAD advanced practitioners and 10 LVAD RNs who were geographically well distributed across the USA. The majority (73%) of respondents worked at centers managing >75 LVAD outpatients and 66% provided care for LVAD patients living in rural areas. Thirty-seven percent of respondents had completed >10 telehealth visits for LVAD patients, and 90% had used telephone visits and 94% video visits. Most respondents (87%) completed telehealth visits for routine care with only 17% using telemedicine visits for acute issues and 10% for post-discharge visits. Fifty-three percent and 26% of providers did not feel comfortable making antihypertensive or diuretic medication changes, respectively, during telehealth visits. Use of remote patient monitoring (RPM) devices for tracking blood pressure or activity levels was low (Figure: top panel). Seventeen percent of providers were unsatisfied with patient care during telehealth visits. The most common barriers to increased adoption of telehealth visits for LVAD patients included patient access to technology and reimbursement considerations (Figure: bottom panel). Conclusion Telehealth visits are being used for LVAD patients but provider comfort level with medication changes during visits is low. Improved patient access to technology for RPM and video visits and expanded reimbursement of telehealth services may help to increase telemedicine usage for LVAD patients.